{"id":2316,"date":"2026-07-30T09:30:00","date_gmt":"2026-07-30T13:30:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2316"},"modified":"2026-07-30T20:42:06","modified_gmt":"2026-07-31T00:42:06","slug":"high-risk-ccus-converges-with-lower-risk-mds","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2316","title":{"rendered":"High-Risk CCUS Converges with Lower-Risk MDS"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Moffitt Cancer Center<\/p>\n

Event Type<\/strong><\/p>\n

Published Research (Peer-Reviewed, Prospective Natural-History Cohort)<\/p>\n

Modality<\/strong><\/p>\n

Risk-stratification scoring (genomic and clinical)<\/p>\n

Asset<\/strong><\/p>\n

Clonal Hematopoiesis Risk Score and Clonal Cytopenia Risk Score (research-stage tools, not clinical assets)<\/p>\n

Target<\/strong><\/p>\n

Risk stratification of clonal cytopenia of undetermined significance (CCUS)<\/p>\n

Disease Area<\/strong><\/p>\n

Clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndrome (MDS)<\/p>\n

Summary<\/h4>\n

A prospective, centrally reviewed Blood study of 409 patients with clonal cytopenia of undetermined significance and 241 with lower-risk myelodysplastic neoplasms found that risk-defined high-risk CCUS had clinical features and event rates comparable with lower-risk MDS. Low- and intermediate-risk CCUS had substantially better outcomes. The result supports risk-adapted surveillance and trial design, but it does not reclassify all CCUS as MDS or establish that preemptive treatment improves outcomes.<\/p>\n

Investigators applied harmonized progression criteria, centralized pathology review, uniform genomic profiling, and two independent tools, the Clonal Hematopoiesis Risk Score and Clonal Cytopenia Risk Score, to a prospective natural-history cohort. Both models stratified CCUS, and the high-risk subset converged clinically with lower-risk MDS.<\/p>\n

The peer-reviewed article appeared online on 29 July 2026 and was recovered during the midday publication reconciliation. The authors propose considering high-risk CCUS for prospective lower-risk MDS trials while supporting conservative management for lower-risk groups.<\/p>\n

Scientific, clinical, and regulatory interpretation<\/h4>\n

The study challenges a morphology-dominant boundary built around dysplasia thresholds. If patients with similar clonal architecture, cytopenias, and event rates are divided primarily by semi-quantitative morphology, trial eligibility and monitoring may not reflect biological risk. Using two independently developed scores and centralized review strengthens the observation.<\/p>\n

Alternative interpretations and validation gate<\/h4>\n

A strong interpretation is that high-risk CCUS represents an early phase of the same disease continuum as lower-risk MDS and should enter prevention or interception trials, supported by the convergence of clinical features and outcomes. A more conservative interpretation is that risk scores identify prognosis without redefining disease, since observational similarity does not prove identical biology or treatment responsiveness and diagnostic MDS criteria remain unchanged. Prospective intervention trials, serial clonal tracking, and reproducibility in diverse cohorts will determine whether risk classification should change clinical action.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Biomarker signal: combined clinical and genomic scores may be more actionable than morphology alone for surveillance intensity and enrollment.<\/li>\n
  • Trial-design signal: high-risk CCUS could become a rational interception population for agents already studied in lower-risk MDS.<\/li>\n
  • Diagnostic signal: the work supports a continuum model while stopping short of revising formal disease definitions.<\/li>\n
  • Cohort: 409 CCUS patients and 241 lower-risk MDS patients, centrally reviewed.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a useful disease-classification and trial-enrichment signal, not an immediate treatment-changing result. The most valuable near-term application is selecting high-risk patients for closer monitoring and prospective research. Treating score-defined high-risk CCUS as established MDS in routine care would exceed the evidence.<\/p>\n

    Company and Product Background<\/h4>\n

    The work was led by investigators from Moffitt Cancer Center and collaborating academic centers using the National MDS Natural History Study. CCUS combines persistent unexplained cytopenia with myeloid-associated somatic mutations but lacks sufficient morphologic or other criteria for MDS. Lower-risk MDS is a clonal marrow neoplasm characterized by ineffective hematopoiesis, cytopenias, dysplasia and\/or defining genomic abnormalities, with variable risk of progression to acute myeloid leukemia.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance is rated 3\/5 with a Positive\/uncertain direction. Confidence in the underlying study facts is High; confidence in the interpretation is Medium-High for prognostic convergence and lower for diagnostic reclassification or treatment implications.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A prospective, centrally reviewed Blood study of 409 patients with clonal cytopenia of undetermined significance and 241 with lower-risk myelodysplastic neoplasms found that risk-defined high-risk CCUS had clinical features and event rates comparable with…<\/p>\n","protected":false},"author":1,"featured_media":2329,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[236,235,224],"class_list":["post-2316","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-clonal-cytopenia-of-undetermined-significance","tag-moffitt-cancer-center","tag-myelodysplastic-syndrome"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2316"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2316\/revisions"}],"predecessor-version":[{"id":2336,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2316\/revisions\/2336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2329"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}